Business Wire

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA ® ▼ (Dinutuximab Beta) in China

Share

EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application (BLA) for QARZIBA®▼ (dinutuximab beta) was accepted by the China National Medical Products Administration (NMPA) and granted priority review. Dinutuximab beta is a targeted immunotherapy approved by the European Medicines Agency (EMA) for the treatment of high-risk neuroblastoma in patients aged 12 months and above who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma with or without residual disease. High-risk neuroblastoma is an aggressive neoplasm and the most common childhood solid tumour that originates outside of the brain. Dinutuximab beta is listed in the first batch of New Drugs in Urgent Clinical Need Marketed Overseas by the NMPA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005558/en/

“Dinutuximab beta represents an important biologic, which is already available to patients with high-risk neuroblastoma in Europe,” commented Xiaobin Wu, Ph.D., General Manager of China and President of BeiGene. “For paediatric patients fighting this disease in China, we are hopeful that dinutuximab beta will soon be available as a new treatment option. Our collaboration with EUSA and the progress thus far demonstrate our joint commitment to bringing high-quality therapies to the people who need them.”

Lee Morley, Chief Executive Officer of EUSA Pharma, said, “This milestone brings us and BeiGene closer to delivering on our promise of bringing innovative cancer and rare disease therapies to patients around the world. We look forward to working with BeiGene and the NMPA to potentially make dinutuximab beta available in China.”

About QARZIBA®▼ (dinutuximab beta)

QARZIBA®▼ is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells. Dinutuximab beta was approved by the European Commission in 2017 and is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, dinutuximab beta should be combined with interleukin-2 (IL-2).

About EUSA Pharma

Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. The company has extensive commercial operations in the United States and Europe, alongside a direct presence in select other markets across the globe. EUSA Pharma is led by an experienced management team with a strong record of building successful pharmaceutical companies and is supported by significant funding raised from leading life science investor EW Healthcare Partners. For more information please visit www.eusapharma.com.

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,700+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

BeiGene Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential approval, launch and opportunity of QARZIBA® in China, future development and potential commercialization activities of the products under the agreement with EUSA, and other information that is not historical information. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

GL-DNB-2000070. November 2020

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

EUSA Media
Rebecca Kerr
+44 7909 703627
media@eusapharma.com

BeiGene Investors
Craig West
+1 857-302-5189
ir@beigene.com

BeiGene Media
Liza Heapes
+1 857-302-5663
media@beigene.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Illumination and Nintendo Announce Theatrical Release Date and Voice Cast for the Super Mario Bros. Animated Film24.9.2021 01:46:00 CEST | Press release

Illumination (HQ: Santa Monica, CA, USA; Founder and CEO: Chris Meledandri) and Nintendo Co., Ltd. (HQ: Kyoto, Minami-ku, Japan; Representative Director and President: Shuntaro Furukawa, “Nintendo” hereafter) today announced that their new animated film based on the world of Super Mario Bros. will be released worldwide during the 2022 holiday season. Universal Pictures will release the film in North America on December 21, 2022, with the release schedule for additional countries and regions to be announced at a future date. The film will be co-financed by Universal Pictures and Nintendo. In addition, the two companies announced the voice actors for the characters Mario (Chris Pratt), Princess Peach (Anya Taylor-Joy), Luigi (Charlie Day), Bowser (Jack Black), Toad (Keegan-Michael Key), Donkey Kong (Seth Rogen), Cranky Kong (Fred Armisen), Kamek (Kevin Michael Richardson) and Spike (Sebastian Maniscalco). Each voice actor was cast for their ability to capture the unique spirit of their c

NuScale Power Signs Memorandum of Understanding with Getka and UNIMOT to Explore SMR Deployment in Poland23.9.2021 19:00:00 CEST | Press release

NuScale Power, Getka Group (Getka) and UNIMOT S.A. (UNIMOT) announced today the three companies have signed a Memorandum of Understanding (MOU) with business purposes including to explore the deployment of NuScale’s small modular reactor (SMR) technology as a coal repurposing solution for existing coal-fired power plants in Poland. Getka is an Oklahoma-based integrated energy company providing construction, and delivery of petroleum, refined products, and alternative energy. Through its Zero Impact Strategy, Getka is focused on reducing emissions output through renewable energy. UNIMOT is a Poland-based multi-energy Capital Group that offers its wholesale and retail customers fuel products, gas and electricity, including renewable energy. This agreement demonstrates the value of international partnership and collaboration in utilizing NuScale’s SMR technology to repurpose coal plants across the country. This press release features multimedia. View the full release here: https://www.bus

Fluence by OSRAM Experts Join Speaker Lineups at Global Horticulture and Cannabis Conferences This Fall23.9.2021 17:54:00 CEST | Press release

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced its upcoming schedule of speakers who will present at virtual and in-person horticulture and cannabis industry conferences this fall. “We’re thrilled our speakers are joining industry thought leaders from across the world to share their deep knowledge with cultivators, researchers, partners and others,” said David Cohen, CEO of Fluence. “At Fluence, our experts lead with science and are dedicated to advancing the industry’s awareness and application of LED lighting technologies to better understand the interaction between light and life. We look forward to connecting with conference participants, engaging in valuable conversations and discussing insights and learnings about what’s possible for LED lighting technology.” Fluence’s roster of speakers includes: NCIA’s Midwest Cannabis Business Conference: Corinne Wilder, vice president of g

ESI Group appoints Francis Griffiths as Executive Vice President of Sales23.9.2021 17:30:00 CEST | Press release

Regulatory News: ESI Group (ISIN Code: FR0004110310, Symbol: ESI) is pleased to announce the appointment of Francis Griffiths as Executive Vice President of Sales, effective October 1st, 2021. He will report to Mike Salari, Corporate COO Revenue Generation, and join the leadership team of Cristel de Rouvray, CEO of the Group. He will be based in the United Kingdom. Francis Griffiths, 57 years old, is a long-standing executive with more than thirty years of experience in the realms of business and technology. He has a long history of success in the global marketplace with technical and scientific software solutions and has experience with the type of transformation we are driving at ESI. He brings to ESI an impressive track record of growth in Test & Measurement, Simulation and Industrial Automation in various industries including Automotive, Aerospace, Heavy Machinery, Communications, Energy, and Electronics. From this point onwards, Francis will be entrusted with leading and overseein

2J Antennas Launches The World’s Smallest 5GNR, WiFi-6E and GNSS Combination 9-in-1 Antennas For Critical Communication Modernization23.9.2021 16:50:00 CEST | Press release

2J Antennas, a global leader in high performance antenna solutions, introduces the new Stellar Series that is designed for a large suite of devices with a focus on sub 6 GHz, 5G NR, 4G LTE, 3G, 2G, WiFi-6E and GNSS technologies. With superior reliability, quality, performance, real time connectivity and smaller size, the Stellar Series caters to law enforcement, medical transportation, fire rescue, and any other applications where mission critical communication is a requirement. This series includes single or up to 9-in-1 configuration choices within the range of 617 MHz to 7125 MHz frequency bands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005703/en/ Stellar Series by 2J Antennas (Photo: Business Wire) The cutting-edge patent pending technology reduces the antenna footprint by 55% while implementing a new double trifilar design and longitudinal resonances for MIMO/ ARRAY configurations that traditionally have mor

Saladax Biomedical Announces Salvatore J. Salamone, Ph.D. Received the Prestigious Dr. C.E. Pippenger Award23.9.2021 16:05:00 CEST | Press release

Salvatore J. Salamone, Ph.D. received the prestigious Dr. C.E. Pippenger Award at the 2021 International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting in Rome, Italy. This award is given to individuals who have made outstanding contributions to the field of Therapeutic Drug Monitoring (TDM). TDM is a field of medical science that seeks to ensure that patients receive a personalized dose of drugs to achieve an optimum therapeutic result. Unfortunately, many medications, such as anticancer, antibiotics, and antifungal treatments, have severe toxicities when overdosed and are ineffective when underdosed. TDM seeks to ensure that the patient receives enough drug to treat the condition but not too much to cause toxicities and potentially death. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005035/en/ Dr. Salvatore J. Salamone (Photo: Business Wire) Dr. Salamone received this aw

HarbourVest Partners Announces Close of Direct Lending Fund23.9.2021 16:00:00 CEST | Press release

HarbourVest Partners, a global private markets asset manager, today announced the final close of its HarbourVest Direct Lending Fund (HDL) at over $892 million in limited partner commitments, including the General Partner commitment. The Fund was oversubscribed and closed above the target size of $600 million. This close follows the firm’s final close of Credit Opportunities Fund II, HarbourVest’s junior credit offering, earlier this year. “We are pleased to mark the final close of our inaugural, dedicated direct lending fund, bringing our total capital under management for credit investments to over $3.3 billion*,” said John Toomey, Managing Director, HarbourVest Partners. “The past year has demonstrated the resilience of the asset class and reinforced our objective to broaden the reach of HarbourVest’s solutions to help clients invest in rapidly growing strategies.” The Fund targets senior credit investments in private equity-backed middle-market companies, predominantly in North Ame